[Therapeutic results in lung diseases caused by atypical mycobacteria].
Between 1972 and 1981, 38 patients suffering from lung disease by atypical mycobacteria were admitted to our institute. 36 out of them were males and 2 females with an average age of 55 years. In 10 patients silicosis was present. The patients received chemotherapy at special combinations using Rifampicin, Ethambutol and one or two additional drugs. 2 patients could be healed by lung lobe resection. In 12 patients x-ray regression could be observed. In the remaining patients, stabilization of the lung lesions and sputum conversion--at least temporarily--could be obtained. Because of multiple drug resistance, the therapy of mycobacteriosis is complicated, and permanent conversion of sputum cannot always be obtained, especially in diseases caused by M. intracellulare-avium. Bacteriological relapses are to be expected in 30 to 40 percent.
D000995:Antitubercular Agents / Q000627:therapeutic use*; D002207:Capreomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000627:therapeutic use; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D002207:Capreomycin; D004917:Erythromycin; D004977:Ethambutol; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Therapieergebnisse bei Lungenerkrankungen durch atypische Mykobakterien.